0001437749-24-000942.txt : 20240209 0001437749-24-000942.hdr.sgml : 20240209 20240109100735 ACCESSION NUMBER: 0001437749-24-000942 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GeoVax Labs, Inc. CENTRAL INDEX KEY: 0000832489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870455038 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: GA ZIP: 30080 BUSINESS PHONE: 678-384-7220 MAIL ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: GA ZIP: 30080 FORMER COMPANY: FORMER CONFORMED NAME: Geovax Labs, Inc. DATE OF NAME CHANGE: 20061002 FORMER COMPANY: FORMER CONFORMED NAME: DAUPHIN TECHNOLOGY INC DATE OF NAME CHANGE: 19940826 FORMER COMPANY: FORMER CONFORMED NAME: SUCCESSO INC DATE OF NAME CHANGE: 19910410 CORRESP 1 filename1.htm govx20240109_corresp.htm

GeoVax Labs, Inc.

1900 Lake Park Drive

Suite 380

Smyrna, Georgia 30080

(678) 384-7220

 

January 9, 2024

 

VIA EDGAR

 

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

 

 

Re:

GeoVax Labs, Inc.
 

 

Registration Statement on Form S-1
 

 

File No. 333-276345

 

Ladies and Gentlemen:

 

In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), GeoVax Labs, Inc., a Delaware corporation (the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-1 (File No. 333-276345) filed with the U.S. Securities and Exchange Commission on January 2, 2024, be accelerated so that the registration statement becomes effective at 5:00 p.m. Eastern Time on Thursday, January 11, 2024 or as soon thereafter as practicable. In this regard, the Registrant is aware of its obligations under the Securities Act.

 

If you have any questions or comments, please contact me or if you prefer, you may contact our counsel, F. Reid Avett of Womble Bond Dickinson (US) LLP, by telephone at (202) 857-4425, or by email at reid.avett@wbd-us.com.

 

 

   

Very truly yours,

  
       
   

GeoVax Labs, Inc.

  
       
 

By:

/s/ Mark W. Reynolds

  
   

Mark W. Reynolds

  
   

Chief Financial Officer